Abstract
Members of epidermal growth factor receptor (EGFR) or ErbB receptor family play a critical role in a wide range of human cancers. In the past decade, there has been a remarkable progress in developing ErbB targeted therapeutics. However, a substantial portion of patients has non-responsive disease or subsequently shows evidence of tumour relapse following initial success with anti-ErbB agents. Improved insights into the biology of ErbB receptor family have led to more effective second- and third-generation anti-ErbB therapies. In this review, we have summarised salient features of the ErbB receptor physiology and highlighted key mechanisms involved in abnormal ErbB signalling in tumorigenesis. The rationale of anti-ErbB receptor therapies are outlined along with key mechanisms proposed for resistance to treatment as well as the current concept of combined anti-ErbB therapies. In conclusion, improved understanding of the molecular pathways that confer resistance to anti-ErbB therapeutics will be essential in minimising tumour resistance to ErbB targeted treatments.
Keywords: EGFR, ErbB, receptor tyrosine kinase, monoclonal antibodies, small molecule inhibitors, cancers, tumorigenesis, tumour resistance, dimerization, gene amplifications
Current Pharmaceutical Design
Title:Targeting the EGFR-family for Therapy: Biological Challenges and Clinical Perspective
Volume: 18 Issue: 19
Author(s): Rachana Patel and Hing Y. Leung
Affiliation:
Keywords: EGFR, ErbB, receptor tyrosine kinase, monoclonal antibodies, small molecule inhibitors, cancers, tumorigenesis, tumour resistance, dimerization, gene amplifications
Abstract: Members of epidermal growth factor receptor (EGFR) or ErbB receptor family play a critical role in a wide range of human cancers. In the past decade, there has been a remarkable progress in developing ErbB targeted therapeutics. However, a substantial portion of patients has non-responsive disease or subsequently shows evidence of tumour relapse following initial success with anti-ErbB agents. Improved insights into the biology of ErbB receptor family have led to more effective second- and third-generation anti-ErbB therapies. In this review, we have summarised salient features of the ErbB receptor physiology and highlighted key mechanisms involved in abnormal ErbB signalling in tumorigenesis. The rationale of anti-ErbB receptor therapies are outlined along with key mechanisms proposed for resistance to treatment as well as the current concept of combined anti-ErbB therapies. In conclusion, improved understanding of the molecular pathways that confer resistance to anti-ErbB therapeutics will be essential in minimising tumour resistance to ErbB targeted treatments.
Export Options
About this article
Cite this article as:
Patel Rachana and Y. Leung Hing, Targeting the EGFR-family for Therapy: Biological Challenges and Clinical Perspective, Current Pharmaceutical Design 2012; 18 (19) . https://dx.doi.org/10.2174/138161212800626148
DOI https://dx.doi.org/10.2174/138161212800626148 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Lipoprotein Subfractions, Uric Acid and Cardiovascular Risk in End-Stage Renal Disease (ESRD) Patients
Current Vascular Pharmacology Modulation of Cardiac Metabolism During Myocardial Ischemia
Current Pharmaceutical Design The Role of Chymase in Vascular Remodeling and Tissue Fibrosis
Current Hypertension Reviews Cancer Treatment-Induced Cardiotoxicity: a Cardiac Stem Cell Disease?
Cardiovascular & Hematological Agents in Medicinal Chemistry Chromatin Remodeling, DNA Damage Repair and Aging
Current Genomics Adiponectin and its Role in Cardiovascular Diseases
Cardiovascular & Hematological Disorders-Drug Targets Stem Cells: Clinical Trials Results The End of the Beginning or the Beginning of the End?
Cardiovascular & Hematological Disorders-Drug Targets Pituitary Dysfunction as a Cause of Cardiovascular Disease
Current Pharmaceutical Design Protein Factors Mediating Selenoprotein Synthesis
Current Protein & Peptide Science Cancer Therapeutics-Related Cardiovascular Complications. Mechanisms, Diagnosis and Treatment
Current Pharmaceutical Design DNA Topoisomerase II Enzymes as Molecular Targets for Cancer Chemotherapy
Current Cancer Drug Targets Bisphenol A as a Factor in the Mosaic of Autoimmunity
Endocrine, Metabolic & Immune Disorders - Drug Targets Stem Cell Based Preclinical Drug Development and Toxicity Prediction
Current Pharmaceutical Design Frontotemporal Lobar Degeneration (FTLD): Review and Update for Clinical Neurologists
Current Alzheimer Research Recent Updates on Current and Upcoming Biomarkers for Cardiovascular Diseases
Current Pharmaceutical Design Impact of Mitochondrial Toxicity of HIV-1 Antiretroviral Drugs on Lipodystrophy and Metabolic Dysregulation
Current Pharmaceutical Design Chlorpyrifos with Age-Dependent Effects in Cardiac Tissue of Male Rats
Current Molecular Pharmacology Mechanisms of Intimal Hyperplasia Learned from a Murine Carotid Artery Ligation Model
Current Vascular Pharmacology The GLUTs Family - Lessons from Transgenic Mice
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents The Role of the Metabolism of Anticancer Drugs in Their Induced-Cardiotoxicity
Current Drug Metabolism